ARK Invest: Is AI the wonder cure for the broken healthcare sector?
Adopting new technology could help pharma and biotech firms fix the expensive and lengthily drug development process, writes Rahul Bhushan
Adopting new technology could help pharma and biotech firms fix the expensive and lengthily drug development process, writes Rahul Bhushan
|
|
The emergence of DeepSeek has challenged markets to consider artificial intelligence more rationally, writes Marc Collantonio
|
|
Excitement around AI is forming a potential bubble that could do permanent damage to investor’s capital, writes Konstantin Leidman
|
|
With investment in AI peaking to $300bn next year, companies need to rethink their business models if they want to deliver for investors
|
|
Heightened tariffs may spur growth in China’s tech sector rather than stunt it as Trump intends, writes Rahul Bhushan
|
|
Three fund managers on stocks that are getting them excited
|
|
Some 66% of investors want to see evidence of improved productivity after mounting speculation around AI’s uses
|
|
The BGF AI Innovation fund, iShares AI Infrastructure UCITS ETF, and the iShares AI Adopters & Applications UCITS ETF
|
|
Hundreds of billions have been pumped into AI, but when will it start producing profit, ask the Liontrust Global Innovation managers
|
|
Investors will benefit over the long-term by from diversifying their AI exposure, rather than piling into a single stock dominating headlines today, writes Brett Winton
|
|
Markets have chosen Nvidia as the ultimate AI winner, but Alison Savas says other companies are stealing its thunder
|
|
In an increasingly unforeseeable world, there are some predictable themes pushing the direction of global markets
|
|